Clinical Studies Sponsored by MacroGenics

Clinical Studies where

Trial Sponsor

Name	NCT Number	Health Conditions in Trial	Clinical Trial Start Date	Study Completion Date	Clinical Trial Study Type
‌ A Study of MGC026 in Participants With Advanced Solid Tumors	NCT06242470	Cervical cancer Bladder cancer Colorectal cancer Hepatocellular carcinoma Sarcoma Endometrial cancer Melanoma Clear cell renal cell carcinoma	2024	2028	Interventional
‌ Flotetuzumab Expanded Access Program	NCT04678466	Acute myeloid leukemia
‌ Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer	NCT02492711		August 24, 2015	June 14, 2022	Interventional
‌ A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults	NCT00515385		2007	2009	Interventional
‌ RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma	NCT00101972	Cancer	2004	2008	Interventional
‌ Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes	NCT01189422		2010	2011	Interventional
‌ Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer	NCT02381314	Melanoma	March 26, 2015	September 26, 2018	Interventional
‌ Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors	NCT02982941	Osteosarcoma Rhabdomyosarcoma Neuroblastoma	2016	May 22, 2019	Interventional
‌ Treatment of West Nile Virus With MGAWN1	NCT00927953	Encephalitis West Nile fever ‌ Meningitis	2009	2011	Interventional
‌ Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)	NCT02152956		June 9, 2014	July 5, 2022	Interventional
‌ Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure	NCT01206504
‌ Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer	NCT00625586	Pancreatic cancer	April 15, 2008	March 18, 2009	Interventional
‌ A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer	NCT05551117		June 13, 2023	2026	Interventional
‌ Tissue Procurement Substudy for Participants in Study CP-MGA271-01	NCT01918930	Melanoma	2013	2016	Interventional
‌ Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck	NCT04129320	Head and neck cancer	2019	2022	Interventional
‌ Phase 1 Study of MGD010 in Healthy Subjects	NCT02376036		2015	2017	Interventional
‌ MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy	NCT03570918		September 25, 2018	September 28, 2021	Interventional
‌ Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma	NCT02248805		2014	July 2, 2018	Interventional
‌ Margetuximab Expanded Access Program	NCT03133988
‌ Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus	NCT00920582		2009	2012	Interventional
‌ A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy	NCT05261191		September 26, 2022	2024	Interventional
‌ MGD019 DART® Protein in Unresectable/Metastatic Cancer	NCT03761017	Colorectal cancer	December 12, 2018	2024	Interventional
‌ Safety Study of MGD009 in B7-H3-expressing Tumors	NCT02628535	Prostate cancer Bladder cancer Mesothelioma Pancreatic cancer Ovarian cancer Melanoma Thyroid cancer Clear cell renal cell carcinoma ‌ Breast Cancer	2015	November 25, 2019	Interventional
‌ Safety Study of MGA271 in Refractory Cancer	NCT01391143	Prostate cancer Bladder cancer Renal cell carcinoma Melanoma Head and neck cancer ‌ Triple-negative breast cancer	2011	April 18, 2019	Interventional
‌ Safety Study of MGAH22 in HER2-positive Carcinomas	NCT01148849	‌ Breast Cancer	2010	June 14, 2022	Interventional

Results per page:

34 results

0 selected

34 results

0 selected